The ongoing global pandemic of COVID-19 poses unprecedented public health risks for
governments and societies around the world, which have been exacerbated by the …

Treating severe COVID-19 patients and controlling the spread of SARS-CoV-2 are
concurrently important in mitigating the pandemic. Classically, antiviral drugs are primarily …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …

The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Effective antiviral treatments for coronavirus disease 2019 (COVID‐19) are needed to
reduce the morbidity and mortality associated with severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …

The coronavirus disease (COVID-19) pandemic, caused by the spread of the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), marked its debut in 2019. To date, this …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …